1134 results for 'erbb3 her'

Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to fight malignancies. Among the notable advancements in this field is the development of immune c

1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive compon

Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu

In the intricate world of cancer biology, a silent conversation is constantly unfolding between tumor cells and their environment. For decades, we viewed this dialogue as a one-way street, with cancer

Bridging ELISA sicher validieren: Praxisleitfaden für Antikörpernachweis Für den routinemäßigen Nachweis von Anti‑Drug‑Antikörpern ist das Bridging‑ELISA das gängigste Format, weil es isotypunabhängi

TIGIT (T cell immunoreceptor with Ig and ITIM domains) has emerged as a promising target in cancer immunotherapy and the treatment of autoimmune diseases. As a checkpoint receptor, TIGIT

V-domain Ig suppressor of T cell activation (VISTA) is an emerging immune checkpoint receptor that plays a key role in suppressing T cell activity within the tumor microenvironment (TME).

Immunotherapy has transformed the landscape of cancer treatment by leveraging the body’s immune system to target and destroy cancer cells. A key player in this process is Inducible T-cell

Introduction to BTLA in Immune Regulation B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that plays a critical role in regulating immune responses by suppressing T

What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers

What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod

Quick Info Section: Key Facts About TalquetamabWhat is Talquetamab?Talquetamab is a novel monoclonal antibody being developed for the treatment of multiple myeloma and other cancers. It

Quick Facts About PlonmarlimabWhat is Plonmarlimab?Plonmarlimab is a monoclonal antibody targeting GM-CSF, a cytokine involved in inflammation and immune responses.How does Plonmarlimab

Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword In the intricate world of cancer biology, some of our body's most potent defense mechanisms can paradoxically turn against us. Cell

For decades, the fight against cancer has been a story of incremental gains. But what if we could fundamentally shift the battlefield, turning the body's own immune system into a precision-guided weap

T cell immunoglobulin and mucin-domain containing-3 (TIM-3) is an immune checkpoint receptor that plays a pivotal role in T cell exhaustion, a state where T cells lose their ability to ef

Glucocorticoid-induced tumor necrosis factor receptor (GITR) is an immune checkpoint molecule that plays a crucial role in regulating T cell activation and survival. In recent years, GITR

Key Facts About TalacotuzumabWhat is Talacotuzumab?Talacotuzumab is a monoclonal antibody designed to target CD123, a protein commonly found on the surface of certain blood cancer cells.

What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What

Explore antigen presentation's crucial role in adaptive immunity and its impact on cancer immunotherapy, highlighting the diversity and function of MHC class I molecules. Key Takeaway